REPArE: Rating Evaluations in Psoriatic Arthritis (PsA) With Enbrel®

Inclusion Criteria: - Presence of psoriasis or previous evidence of psoriasis documented by a dermatologist as part of usual care - At least one of the following forms of PsA:

1. Distal interphalangeal (DIP) involvement (inflammatory)
2. Polyarticular arthritis, absence of rheumatoid nodules and presence of psoriasis
3. Arthritis mutilans
4. Asymmetric peripheral arthritis or
5. Spinal involvement - Active psoriatic arthritis at the time of the study enrollment - Subjects must demonstrate greater than 3 swollen joints and greater than 3 tender/painful joints - Greater than 18 years of age at the time of consent - Able to start Enbrel® therapy per the approved product monograph - Informed consent must be provided before any study specific procedures are performed Exclusion Criteria: - Active infections at time of initiating Enbrel® therapy - Evidence of skin conditions (e.g., eczema) other than psoriasis that would interfere with evaluations of the study medication - A malignancy, other than basal cell carcinoma of the skin or, in situ carcinoma of the cervix, within the past 5 years - Known hypersensitivity to Enbrel® or any of its components - Subjects receiving, or who have received: * Remicade® (infliximab) in the previous 3 months or * Humira® (adalimumab) in the previous 3 months or * Kineret® (anakinra) in the previous 15 days - Subjects receiving or who have received Enbrel® - Treatment with any investigational therapy in the 30 days prior to enrollment or during the study - Active guttate, erythrodermic or pustular psoriasis at the time of screening - Presence of any significant and uncontrolled medical condition, which in the Investigator's opinion, precludes the use of Enbrel® as outlined in the product monograph - Sepsis or at risk of septic syndrome - Subjects not available for follow-up assessment - Concerns for subject's compliance with the protocol procedures